SC 13G/A: Viridian Therapeutics, Inc.\DE
Ticker: VRDN · Form: SC 13G/A · Filed: Feb 14, 2024 · CIK: 1590750
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Viridian Therapeutics, Inc.\DE.
Risk Assessment
Risk Level: low
Filing Stats: 1,814 words · 7 min read · ~6 pages · Grade level 11.1 · Accepted 2024-02-14 09:01:13
Key Financial Figures
- $0.01 — INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti
Filing Documents
- deeptrack-vrdn123123a2.htm (SC 13G/A) — 102KB
- 0001172661-24-000950.txt ( ) — 103KB
(a)Name of Issuer
Item 1. (a)Name of Issuer VIRIDIAN THERAPEUTICS, INC.
(b)Address of Issuer’s Principal
Item 1. (b)Address of Issuer’s Principal Executive Offices 221 Crescent Street, Suite 401 Waltham, MA 02453
(a)Names of Persons Filing
Item 2. (a)Names of Persons Filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
( b)Address
Item 2. ( b)Address of Principal Business Office: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c) Citizenship
Item 2. (c) Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)Title of Class of Securities
Item 2. (d)Title of Class of Securities Common Stock, $0.01 par value (the “Common Stock”)
(e) CUSIP No
Item 2. (e) CUSIP No.: 92790C104 CUSIP No. 92790C104 SCHEDULE 13G/A Page 6 of 9 Pages
If
Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No. 92790C104 SCHEDULE 13G/A Page 7 of 9 Pages Item 4.Ownership Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2023, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 54,333,308 shares. Item 5.Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial Item 6.Ownership of More Than Five Percent